INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.

EyePoint (EYPT) disclosed that its Phase 3 pivotal trial topline results for DURAVYU™ did not meet the primary endpoint—change from baseline in best corrected visual acuity vs 2 mg aflibercept in the entire dataset. Following the August 17, 2026 announcement, the stock fell $9.88 (66.98%) to close at $4.87. Separately, Pomerantz LLP is investigating potential securities fraud or unlawful business practices, adding overhang for equity holders.

Analysis

EYPT has shifted from a clinical-story stock to a capital-structure story. Once a lead asset loses commercial credibility, the equity usually rerates to the value of optionality, not the original peak sales case; that means the next 1-3 months are more about cash runway, dilution risk, and whether management can point to a credible alternate development path. The litigation headline is not the economic driver; it simply increases legal expense and raises the probability of shareholder claims, but the real damage is that institutional buyers often step away until the financing overhang clears.

Competitive read-through is modestly positive for incumbents, especially REGN, because failed sustained-release/delivery approaches reduce the odds of near-term physician switching away from standard anti-VEGF regimens. More broadly, this removes a potential wedge for smaller ophthalmology challengers that were counting on convenience as a differentiation lever; if efficacy is not clearly superior, the market will default back to established efficacy and reimbursement certainty. In that sense, the winner is not just REGN but the whole incumbent category versus speculative delivery-platform names.

The contrarian point is that much of the damage is already reflected in the one-day collapse, so chasing EYPT lower from here is poor risk/reward unless there is an imminent dilution or reverse-split catalyst. What could reverse the trend is not a legal update but a balance-sheet event: a partner, asset sale, or cash runway disclosure that defers financing by >12 months. Absent that, the stock remains a potential value trap rather than a clean short, because the easy downside has largely been repriced and borrow/volatility can punish late shorts.

Key Decisions for Investors

• Buy REGN vs. short EYPT on a relative-value basis over the next 1-3 months; thesis is that incumbents regain share-of-mind while EYPT trades as a financing overhang. Risk: if EYPT secures a partner or announces cash runway >12 months, cover the short.
• Do not initiate fresh outright shorts in EYPT after the collapse; wait for a 15-25% relief rally or a failed financing bounce to improve entry. Falsifier: explicit dilution plan priced above current levels with no immediate cash need.
• Set a catalyst alert on EYPT for next earnings/cash runway disclosure and any strategic transaction update within 30-60 days. If management cannot show a credible alternate program or runway extension, downside can resume despite the already large drawdown.
• Use REGN weakness as a tactical long-only entry, but size modestly; this is a read-through trade, not a fundamental re-rating. Falsifier: evidence that the failed competitor had no physician-sentiment impact and that share trends are unchanged.